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Background In 2009, there were 8273 local screening laboratories, 254 confirma-
tory laboratories, 35 provincial confirmatory central laboratories and
1 National AIDS Reference Laboratory (NARL) in China. These
laboratories were located in Center for Disease Control and
Prevention (CDC) facilities, hospitals, blood donation clinics, ma-
ternal and child health (MCH) hospitals and border health quaran-
tine health-care facilities.
Methods The NARL and provincial laboratories provide quality assurance
through technical, bio-safety and managerial training; periodic pro-
ficiency testing; on-site supervisory inspections; and commercial
serologic kit evaluations.
Results From 2002 to 2009, more than 220 million HIV antibody tests were
performed at screening laboratories, and all reactive and indeter-
minate samples were confirmed at confirmatory laboratories. The
use of highly technically complex tests, including CD4 cell enumer-
ation, viral load, dried blood spot (DBS)-based early infant diagno-
sis (EID), drug resistance (DR) genotyping, HIV-1 subtyping and
incidence assays, have increased in recent years and their perform-
ance quality is closely monitored.
Conclusion China has made significant progress in establishing a
well-coordinated HIV laboratory network and QA systems.
However, the coverage and intensity of HIV testing and quality
assurance programmes need to be strengthened so as to ensure
that more infected persons are diagnosed and that they receive
timely prevention and treatment services.
Keywords HIV/AIDS, laboratory network, quality control, quality assurance,
proficiency testing
Introduction
The first reported HIV cases in China were found
among foreign travellers in 1985 and the first indi-
genous infections were identified in 1989 among
injection drug users (IDUs) in Yunnan province.
1
Subsequently, HIV infections spread to Henan prov-
ince through contaminated plasma collection and to
Xinjing Uygur Autonomous Region by IDUs. Recently,
HIV transmission through sexual contact has
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ii72increased for both women and men who have sex
with men.
1 In 2009, the national HIV prevalence
was 0.057%, and the number of HIV-infected persons
was estimated to be 740000.
2 Since the late 1980s, a
series of national strategic, managerial and technical
plans have been set up to build a tiered laboratory
system to accurately identify infected persons. Free
HIV antibody screening has been provided to the gen-
eral public since 2004 to increase testing coverage.
Free CD4 cell enumeration, viral load (VL) determin-
ation and antibody confirmatory testing were pro-
vided in 2004, 2006 and 2008, respectively.
3 By the
end of 2009, 8273 serologic screening laboratories
were in place and more than 220 million cumulative
screening tests had been performed nationwide since
2002.
4 To monitor trends in incidence, the efficacy of
anti-retroviral treatments (ARTs) and vertical trans-
mission, laboratory capacity was further expanded to
include more sophisticated molecular methodologies.
In this report, we describe the hierarchical structure,
function, measures and challenges of the laboratory
expansion process.
The Establishment of an HIV/AIDS
Testing Laboratory Network
The establishment of the Chinese HIV laboratory net-
work can be divided into three developmental stages.
The initial stage, from 1985 to 1988, was a spontan-
eous reaction to the HIV epidemic outside of China.
The laboratory capacity was inadequate to carry out
timely testing and there was a general lack of
scientific knowledge, technical skills and specialized
equipment. Recognizing the need for an organized na-
tional response, China formulated a national HIV/
AIDS prevention plan and additional HIV/AIDS sur-
veillance regulations in 1987, focusing on serologic
surveillance in most-at-risk populations and of blood
products.
The second stage of laboratory development
occurred from 1989 to 2002. Initially, the role of the
national reference laboratory was played by the
Institute of Virology at the Chinese Academy of
Preventive Medicine. In 1998, the National AIDS
Reference Laboratory (NARL) was established in the
National Center for AIDS Prevention and Control
of Chinese Center for Disease Control and
Prevention (China CDC). By 2002, 44 confirmatory
laboratories and 1870 screening laboratories were
operational, which conducted more than 22000 con-
firmatory and 12.3 million screening tests (Figure 1).
The third stage of laboratory development began in
2003 when China equipped its HIV network labora-
tories with contemporary instruments, and used stan-
dardized operating procedures to homogenize
operations nationwide. Sophisticated molecular meth-
odologies, optimized quality assurance programmes
and an electronic data reporting system were de-
veloped. In 2004, China issued national HIV/AIDS
management guidelines
5 to delineate the overall con-
figuration and managerial structure of a tiered screen-
ing and confirmatory laboratory network (Table 1).
The base of the network was comprised of screening
laboratories located mostly in county-level public
health facilities and hospitals. They primarily
Figure 1 The yearly increase of screening (A) and confirmatory and confirmatory central laboratories (B) and the
respective tests performed in China between 1992 and 2009. Diamonds: numbers of laboratories; squares: numbers of
tests performed
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munosorbent assays (ELISA) and rapid tests (RTs).
All reactive specimens were transportedto confirmatory
laboratories where western blot (WB) assays were used
to confirm results before a positive report was issued.
The number of screening laboratories tripled from
2382 in 2003 to 8273 in 2009 (Figure 1). Screening
laboratoriesusedcontrolspecimensprovidedbyreagent
kits and external quality controls provided by commer-
cial sources to perform run-to-run Levey–Jennings con-
trol charts
6 and ensure the test range was within the
prescribedrange. The totalnumberofconfirmatorycen-
tral and confirmatory laboratories increased from 48 in
2003 to 289 in 2009. The number of screening and con-
firmatory tests performed in 2009 were 52 million and
88498, respectively (Figure 1).
The screening laboratories were widely distributed
in county CDCs, hospitals, blood banks, maternal
and child health (MCH) clinics and border quarantine
health-care facilities. Originally, these screening
laboratories were located in CDC facilities; but by
the end of 2009, 57% were in the hospital system.
RTs were introduced into China in 1999 and their
use followed the WHO recommendations of using a
serial testing algorithm.
7 Initially, RTs were used pri-
marily in prevention of mother-to-child transmission
(PMTCT) programmes to quickly identify HIV-
infected mothers. It is now widely used in voluntary
counselling and testing (VCT) facilities, hospital sur-
gery and out-patient departments and for hard-to-
reach populations such as men who have sex with
men (MSM) or female sex workers in prefecture
and lower health-care facilities. Beginning in 2006,
the NARL conducted a proficiency testing (PT)
evaluation on confirmatory laboratories, and, by
2009, 269 of the 289 (93%) laboratories participated
in the programme.
Provincial and confirmatory laboratories performed
CD4 enumeration, HIV-1 incidence tests and molecular
assays. In 2009, 84 of these laboratories conducted VL
tests, 12 dried blood spot (DBS)-based polymerase
chain reaction (PCR) for early infant diagnosis (EID),
6 drug resistances (DRs) and 15 BED-based incidences
(Table 2). Because of the expansion of ART, the annual
numbers of CD4 and VL tests performed increased by 52
and 90%, respectively, from 2008 to 2009. In 2009, na-
tionally, 238385 CD4 enumeration, 63408 VL and 3946
DR tests were completed.
Laboratory and Staff Certification
and Staff Training
HIV laboratory and staff certification systems have
been in place since 1988. Laboratories have to be con-
structed according to the national HIV/AIDS manage-
ment guidelines.
5 A serologic laboratory is required to
have three operational areas: ‘clean’, ‘semi-contami-
nated’ and ‘contaminated’. PCR-based tests (i.e. VL,
EID, DR and subtyping) have to be conducted in a
facility with three separate rooms for reagent prepar-
ation, blood sample processing and amplification.
Laboratory staff are required to take specific biosafety
and test-specific training and biannual refresher
training in order to perform clinical testing.
Provincial health authorities and technical HIV ex-
perts perform annual laboratory inspections and
issue operational permits. Laboratories without
Table 1 Distribution and major functions of each tier of the HIV testing facilities in China
Facilities Number Location Major functions
NARL 1 China CDC in Beijing Formulation of national testing guidelines,
implementation and coordination of national
testing projects, provision of quality assurance
programmes, supervision, evaluation of novel
technologies and reagent kits
Confirmatory central
laboratories
35 One each in 31 provincial
CDCs and four other special
organizations
a
Formulation of provincial policies and conduct-
ing in-province staff training, reagent kit
evaluations, supervisory visits of lower tier
laboratories and provincial serologic PT
programmes
Confirmatory laboratories 254 Prefecture CDCs, large
hospitals, Border Health
Quarantine and other
facilities
Conductance of confirmatory tests to verify all
specimens screened reactive or indeterminate
from the screening laboratories, provision of
QA, training and supervision to screening
laboratories
Screening laboratories 8273 County CDCs, hospitals, blood
stations, MCH clinics,
Border Health Quarantine
and other facilities
Conductance of screening tests including ELISA
and RTs
aXinjiang Production and Construction Corps, Border Health Quarantine, Armed Forces and Military Police Bureau. MCH: maternal
and child health; PT: proficiency testing; RTs: rapid tests.
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ordered to close until corrective remedies are insti-
tuted. If a laboratory is closed, the NARL and the
provincial CDC provide onsite supervisory visits and
training to raise the operational level of both staff
and laboratory procedures.
With the input from domestic and international ex-
perts, the NARL formulated and established
HIV-related technical guidelines.
8–10 The national
HIV/AIDS testing technical guidelines
11 were published
in 2004 and revised in 2009 to incorporate recent meth-
odological changes and international recommenda-
tions. The NARL is responsible for the dissemination
of the policies to laboratory staff through training
workshops, electronic notifications and the
semi-annual laboratory network newsletter
11 distribu-
ted to all screening facilities. Training is conducted in a
top-down step-wise manner. The NARL trains staff
from provincial and confirmatory laboratories. These
trainees would in turn provide training to the staff at
the lower level laboratories. The NARL is responsible for
national training courses for sophisticated tests includ-
ing BED, EID, DR and subtyping. Provincial laboratories
are responsible for sub-provincial training on WB, RTs,
ELISA and CD4. In 2009, the 229 technical staff from
the 35 provincial laboratories received an average of 2.7
trainings per person. The 27886 technical staff from the
screening laboratories received 0.95 trainings per
person. The training used to prepare the laboratory
staff to obtain operational permits was conducted in
laboratories with repetitious hands-on practice. In add-
ition to the technical staff,  10% of the trainees were
non-laboratory staff responsible for general quality as-
surance and procurement service with classroom train-
ing. The inclusion of these staff in the training
enhances co-ordination of operations so that reagent
procurement and equipment maintenance would be
carried out appropriately. The importance of
laboratory-related biosafety and prevention of occupa-
tional exposure was recognized. Post-exposure prophy-
lactic treatment for HIV was available. In 2009, 920
accidental exposures were reported by personnel work-
ing in HIV control and prevention programmes and
laboratories.
5 Six hundred and eighty-four persons
received ART prophylaxis, counselling and follow-up.
No seroconversions were reported.
PT Programmes
To build and strengthen its own capacity, theNARL first
participated in several international PT programmes.
NARL staff were trained in HIV laboratories in western
countries to learn to prepare PT materials. It also parti-
cipated in the following programmes: (i) College of
American Pathologists’ HIV WB and p24 antigen
tests; (ii) U.S. CDC’s incidence assay,
12 and
DBS-based EID detection
13; (iii) Rush-Presbyterian-St
Luke’s Medical Centeron VLand DR QA programmes
14;
(iv) Australia NationalSerology ReferenceLaboratory on
antigen and antibody tests
15; and (v) CD4 PT provided
by United Kingdom’s National External Quality
Assessment Site programme
16 and Canadian National
Immunology programme for the Quality Assessment
and Standardization of Immunological Measures
Relevant to HIV/AIDS.
17 The NARL began offering its
own ELISA and WB PT programmes to domestic labora-
tories in 2004 (Table 2). In 2009, these programmes
were expanded to cover RTs, BED, CD4, VL,
DBS-based EID, DR and subtyping. The laboratory
coverage in ELISA, WB, RTs, CD4 and viral load was
100% (289/289), 100% (289/289), 93% (269/289), 74%
(234/317) and 94% (79/84), respectively. Provincial con-
firmatory central laboratories also offered PT
Table 2 The establishment and participants of various PT programmes organized and offered by the NARL
Categories Tests
Programme
initiation
year
No. (coverage)
of participating
laboratories
a in
2009 (%)
Frequency
(No. per year)
Serologic tests ELISA 2004 289 (100) 3
WB 2004 289 (100) 3
RT 2006 269 (93) 3
Incidence (BED) 2006 15 (100) 2
Immunologic test CD4 2004 234 (74) 2
Virologic tests VL 2005 79 (94) 2
DBS for EID 2006 12 (NA) 2
DR 2006 6 (NA) 1
Subtyping 2006 12 (NA) 2
aSerologic PT programmes were only offered to confirmatory central and confirmatory laboratories. Provincial confirmatory central
laboratories were responsible for the serologic QA of their respective screening laboratories. The numbers of laboratories performing
the tests of high complexity (i.e. CD4, VL, BED, DR and subtyping) are small. Some of these laboratories were sub-confirmatory
laboratories in high-HIV-prevalent areas. NA: data not available in 2009.
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2009, 97% (34/35) of confirmatory central laboratories
provided this service to screening laboratories. The
coverage of 29 provinces was 100%, but one province
had a low coverage of 25% because of the lack of human
resources and experience.
Serologic and virologic PT specimens were sent to
participating laboratories using cold chain transport.
CD4 PT specimens were sent at ambient temperature.
Participating laboratories were required to report the
results back to the NARL electronically. PT results
were published anonymously in the Laboratory
Network Newsletter.
11 However, NARL personnel pro-
vided feedback and discussed findings with laboratory
staff. If a laboratory exhibited low performance, the
NARL conducted on-site visits to resolve problems.
Problems identified included transcriptional error or
reporting specimens not pertaining to the PT
programme (65%) and delay of reporting (35%).
Technical managers of provincial laboratories partici-
pated in the quality monitoring process. With the ex-
ception of one confirmatory central laboratory in 2008
and another one in 2009, all others provided ELISA
PT for their constituent screening laboratory, similar
to the process used by the NARL.
Laboratory Supervisory Evaluations
and Inspections
On-site laboratory evaluations are conducted annually,
as stipulated by the National Management Regulation
of HIV/AIDS Detection and the National Technical
Guidelines for Detection of HIV/AIDS. The evaluation
coversstafftraining,biosafety,documentationofstand-
ard operating procedures, record keeping equipment
maintenance and laboratory performance. The NARL
is responsible for the evaluation of provincial labora-
tories. They, in turn, evaluate lower level laboratories.
All inspection results and resultant actions are reported
to the NARL. In 2009, the NARL inspected 2963
WB-positive specimens nationwide and found the
average turnaround time (TAT) for reporting was
5 working days (range: 1–21 days). The one with the
longest TAT was 21 working days and occurred in a
laboratory located in a region of low HIV prevalence
where the number of specimens required to be
confirmed was small and thus the test was not done
until a larger number of specimens was collected. This
laboratory was instructed to forward the specimens
to other laboratory to complete the tests in a timely
manner.
Evaluation of Diagnostic Reagent
Kits
In 2002, the NARL and provincial CDCs adopted a
multi-province evaluation to determine the sensitivity
and specificity of commercial HIV antibody diagnostic
kits in China (Table 3). In 2008, the NARL and five
CDCs in high-HIV-prevalence areas (Anhui, Sichuan,
Guangxi, Guangdong and Guizhou) jointly evaluated
16 ELISA and 12 RT kits
18 after they had received
approval from China’s State Food and Drug
Administration (Table 3). Kits were purchased
Table 3 Evaluation of the performance of commercial HIV antibody diagnostic ELISA and RT kits (2002–08)
Year
ELISA RT
Number of
kits
Sensitivity (%)
Average (range)
Specificity (%)
Average (range)
Number of
kits
Sensitivity (%)
Average (range)
Specificity (%)
Average (range)
2002 Domestic 10 99.10 (97.88–100) 98.41 (96.49–99.58) – – –
Foreign 1 99.65 99.40 – – –
2003 Domestic 11 99.75 (98.98–100) 96.72 (94.82–99.10) 4 94.37 (91.48–96.77) 97.72 (94.68–99.77)
Foreign 2 99.61 (99.21–100) 98.41 (98.09–98.73) 3 98.31 (96.71–99.15) 98.10 (97.77–98.61)
2004 Domestic 15 99.47 (82.35–100) 91.87 (83.00–99.50) 6 89.48 (83.33–95.24) 98.33 (97.61–99.52)
Foreign 3 99.61 (98.82–100) 97.50 (96.50–98.00) 4 92.26 (80.95–97.62) 97.85 (96.65–99.52)
2005 Domestic 13 99.29 (96.64–100) 94.16 (90.75–97.24) 7 97.81 (95.73–99.15) 97.82 (95.76–99.58)
Foreign 3 99.44 (99.16–100) 98.68 (97.80–99.56) 5 98.44 (96.58–99.15) 98.45 (95.34–99.58)
2006 Domestic 14 99.65 (98.04–100) 97.91 (94.86–99.21) 8 99.23 (96.91–100) 97.99 (94.64–99.23)
Foreign 3 99.67 (99.02–100) 98.41 (96.84–99.21) 5 98.76 (95.88–100) 98.71 (97.70–100)
2007 Domestic 11 99.91 (99.04–100) 99.38 (97.97–99.75) 11 94.83 (84.21–100) 99.09 (94.62–100)
Foreign 3 100 98.90 (97.46–99.75) 3 98.31 (96.71–99.15) 98.10 (97.77–98.61)
2008 Domestic 13 99.53 (97.69–100) 98.72 (94.61–100) 9 98.09 (87.50–100) 99.51 (98.04–100)
Foreign 3 100 98.20 (94.61–100) 3 100 99.51 (99.02–100)
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panels previously confirmed by WB. The foreign RT
kits evaluated had an average sensitivity of 100%
and a specificity of 99.51% (range: 99.02–100%). The
domestic RT kits had an average sensitivity of 98.09%
(range: 87.5–100%) and specificity of 99.51% (range:
98.04–100%). One domestic kit performed especially
poorly with a sensitivity of 87.5% and specificity of
100%. The finding of an RT kit with suboptimal per-
formance strengthens the notion that frequent inspec-
tions of domestic products are important. The kit
performance data were disclosed in the China CDC
web site and published in the China AIDS
Laboratory Network Newsletter.
18 Evaluations of this
kind convey a message to domestic manufacturers to
continue to improve their manufacturing technologies
and enhance product quality.
Future Challenges and Conclusion
China has established a well-defined HIV laboratory
network along with national and provincial QA sys-
tems to attain a high quality of testing. However, nu-
merous challenges remain. The laboratory network
follows a top-down hierarchical management ap-
proach. Because of the high testing volume and low
number of staff, there is often insufficient human re-
sources. With rapid technological advancements and
guideline modifications, staff need constant training,
particularly in the areas of CD4 and VL testing.
Technical guidelines from the NARL are broad and
thus may not be understood by staff at lower levels.
Most instruments use English as the operating lan-
guage, which presents problems for the technical staff
at the confirmatory laboratory level. With the ex-
pected expansion of RT use, maintaining RT quality
will become a challenge. The NARL and provincial
CDCs will increase RT testing training and standar-
dized record keeping in testing facilities as recently
recommended by Parekh et al.
19
Another challenge is the distribution of laboratory
equipment. More than one brand of molecular testing
instrument may be present in the same facility. This
leads to low productivity and work quality. Many
laboratories performing CD4 and VL do not participate
in the PT programmes. These challenges will need to
be resolved to guarantee sound development of the
Chinese HIV/AIDS testing laboratory network and its
QA system.
The developmental history of the Chinese HIV/AIDS
testing laboratory network and QA system is reliant
on strong financial support from central and local
governments. The role of the NARL in laboratory net-
work development, QA and new technology research
is important and the effectiveness well documented.
Technical research and method evaluations carried
out by the NARL, such as HIV diagnosis technologies
and strategies,
20 HIV-1 VL,
21 EID,
22 incidence
assay
12,23–26 and DR testing,
27,28 have offered key sci-
entific basis for the establishment of national tech-
nical guidelines and the application of new
technologies. Provincial laboratories play an important
role. These laboratories are pivotal in the training
and dissemination of new technology, QA and
site-directed technical support at the provincial level.
They serve as the bridge linking the NARL with rural
laboratories. In addition, frequent international co-
operation and communications have produced con-
structive suggestions and ideas for the laboratory
network and QA/QC development. The challenges
China is facing are numerous. The majority of in-
fected persons are still unaware of their infection
status,
2 and testing CD4 or VL in patients who
reside in hard-to-reach rural areas prior to and post-
ART treatment is difficult. The low-cost point-of-care
technologies such as CD4 measurement,
29 with easy
instrument maintenance and simple QA procedures,
may provide one of the solutions needed in many
resource-constrained areas in China in the future.
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KEY MESSAGES
  A well-co-ordinated comprehensive HIV laboratory network and QA systems have been established in
China.
  Coverage and intensity of HIV testing and quality assurance programmes remain to be strengthened.
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